An update on Biocon and biosimilars

Last Tuesday, we wrote on Kiran Mazumdar Shaw and the future of her Bengaluru-based biopharmaceutical company Biocon. If you haven’t read that piece, we’d recommend you do.

In that story, we pointed out that Biocon Biologics, the company’s biologic drugs division, is the only Indian company that has permission from the US Food and Drug Administration to sell a portfolio of biosimilars in their country. It also has permission to sell biosimilars in Europe, Japan and Australia. Biocon’s focus on biosimilars over the past decade has now placed it in a prime position to take advantage of one of …


T Surendar

Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.

Executive Editor